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H.M. Gonzalez et al. / Alzheimer’s & Dementia 15 (2019) 1507-15151508Discussion: MCI prevalence varied among Hispanic/Latino backgrounds, but not as widely as re-
ported in the previous studies. CVD risk and depressive symptoms were associated with increased
MCI, whereas APOE4 was not, suggesting alternative etiologies for MCI among diverse His-
panics/Latinos. Our findings suggest that mitigating CVD risk factors may offer important pathways
to understanding and reducing MCI and possibly dementia among diverse Hispanics/Latinos.
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Hispanics/Latinos (henceforth Latinos) represent nearly
one-fifth of the United States and 40% of its two most popu-
lous states, California and Texas [1]. By 2060, the census
projects that Latinos (In this study, we refer only to Latinos
with backgrounds from Spanish-speaking regions in North
and South America) will represent nearly one-third of Amer-
icans and that the Latino elderly population (.65 years) will
nearly quadruple [2]. Over the next 40 years, Latinos are pro-
jected to have the largest increase in Alzheimer’s disease and
related dementia (ADRD) cases [3], based on prevalence es-
timates ranging from 21% among US Caribbean (Domin-
ican, Puerto Rican) to 5% among Mainland Latinos
(Mexican and Central Americans) from two large and inde-
pendent studies in New York and northern California [4,5].
Additionally, the differences between Caribbean and Main-
land Latinos for cognitive impairment were 35.2% and
4.8%, respectively [4,5]. These extant prevalence estimates
are 20 years old and have been the extent of our understand-
ing of Latino ADRD epidemiology to date.
Latinos share regional forms of the Spanish language, but
their cultural histories, genetic ancestries, and health profiles
are diverse [6,7], which have important but understudied and
poorly understood implications for Latino health in general
and age-related neurodegenerative disorders specifically.
Striking differences in ADRD prevalence have been re-
ported between African admixed Caribbean Latinos and
Mainland Latinos of mostly Amerindian ancestry [4,5].
Furthermore, risks for ADRD may vary by continental
ancestry. Associations between apolipoprotein E (APOE) 4
and ADRD, an important genetic risk among whites, have
shown little to no relationship with ADRD in Caribbean
Latinos and mixed associations among Mainland Latinos
[5,8,9]. Highly prevalent cardiovascular disease (CVD) risks
(e.g., diabetes) vary among Latino backgrounds, which may
contribute to excess MCI and ADRD among diverse Latinos
[10]. Moreover, understanding and preventing CVD would
likely open opportunities to prevent excess cognitive decline
and dementia by reducing stroke risk [11].
Latinos are an important and growing part of American
society, which will only increase in significance in the com-
ing decades. There are major gaps in Latino dementia
research, which form scientific barriers to the field and USpublic health, and updated Latino dementia information is
needed. Additionally, new biomarker and genomic tools
expand our understanding of neurodegenerative processes
and provide insights into disease prevention and therapeutic
targets. It will be vital to know precisely how these tools
inform current understanding of dementia disease processes
among diverse Latinos. Thus, the goal of this study is to
clarify the prevalence and correlates of MCI among under-
studied and unstudied diverse Latinos. We also sought to
replicate previous research by dividing Latinos into 3 groups
of Caribbean, Mainland, and Cuban backgrounds.2. Methods
2.1. Study design
The Study of Latinos–Investigation of Neurocognitive
Aging (SOL-INCA) is an ancillary study of the Hispanic
Community Health Study/Study of Latinos (HCHS/SOL).
HCHS/SOL and SOL-INCA study designs and rationales
are available elsewhere [12,13]. HCHS/SOL is a multisite,
population-based, prospective cohort study of CVD risks
among Latinos (Baseline years 2008–2011). HCHS/SOL
survey data collection procedures were implemented to yield
representative estimates of diverse Latinos in four targeted
US metropolitan areas: Bronx, NY; Chicago, IL; Miami,
FL; and San Diego, CA. Each field center enrolled about
4000 eligible, self-identified Latino adults (18–74 years
old; N 5 16,415). Biospecimens (e.g., blood) were assayed
for CVD risk factors (e.g., triglycerides) and stored for later
studies. Genetic data were collected only from participants
consenting for genetic testing. Detailed HCHS/SOL sam-
pling methods have been published elsewhere and on the
HCHS/SOL website: https://sites.cscc.unc.edu/hchs/.
Baseline cognitive testing at HCHS/SOL visit 1 (base-
line) included only middle-aged and older (45–74 years) par-
ticipants who were oversampled (n 5 9714) in the cohort.
The Neurocognitive Reading Center trained and supervised
bicultural/bilingual technicians who administered the brief
cognitive battery, which included 4 tests: (1) six-item
screener (SIS; mental status) [14]; (2) Brief-Spanish English
verbal learning test (B-SEVLT; verbal episodic learning and
memory) [15]; (3) word fluency (WF) [16]; and (4) digit
symbol subtest (DSS; processing speed, executive function)
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participate because of health limitations and/or refusals.
SOL-INCA cognitive tests were administered to HCHS/
SOL participants who returned for visit 2, which occurred
on an average of 7 years after visit 1.We expanded the cogni-
tive battery to derive anMCI research diagnosis based on the
National Institute on Aging-Alzheimer’s Association (NIA-
AA) criteria [18]. In addition to visit 1 tests, we included the
Trail Making Test (TMT, parts A&B, executive function)
and NIH Toolbox Picture Vocabulary Test (PVT; general
premorbid cognitive function), self-reported cognitive
decline (Everyday Cognition-12; eCog12) and instrumental
activities of daily living (a measure of functional impair-
ment) [19,20]. The PVTwas used to assess premorbid cogni-
tive function because these scores remain stablewith age and
in later neurodegenerative stages, and to control for potential
educational quality test biases [21]. At HCHS/SOL visit 2,
the Coordinating Center identified 7420 potentially eligible
participants for the SOL-INCA. Inclusion criteria were (1)
visit 2 completion (aged 50 years and older at visit 2) and
(2) visit 1 neurocognitive testing completion. Of this group,
222 were determined to be ineligible, 569 were eligible but
refused to participate, and 6377 were eligible and agreed to
participate. The overall response rate for the SOL-INCA of
eligible participants was 88.7%. Eligible participants return-
ing for SOL-INCA had largely similar baseline characteris-
tics compared with those who were not included in the study
(Supplementary Table 1). Furthermore, to guard against any
possible biases by sample attrition, the HCHS/SOL Coordi-
nating Center generated study-specific calibrated probability
weights that were used in our analyses to adjust for nonre-
sponse and allow generalization of estimates to the HCHS/
SOL metropolitan area target populations aged 50 years
and older.
MCI diagnostic criteria in SOL-INCA were operational-
ized and implemented to generate four NIA-AA criteria:
(1) any cognitive score in the mildly impaired range (i.e.,
from 21 to 22 SD) compared with SOL-INCA internal
robust norms adjusted for age, education, sex, and PVT
scores; (2) significant cognitive decline (20.055 SD/
year) from visit 1; (3) self-reported cognitive decline
(eCog12); and (4) no or minimum functional (instrumental
activities of daily living) impairment [18]. AD biomarkers
(e.g., amyloid b [Ab]) were unavailable in the SOL-INCA.
We included both cognitive impairment and significant
cognitive decline to reduce false positive bias. Participants
with severe cognitive impairment (below 22 SD relative
to SOL-INCA robust norms and with significant functional
impairment) were not included in these MCI prevalence
estimates.
We examined MCI in the six HCHS/SOL backgrounds
(Central American, Cuban, Dominican, Mexican, Puerto Ri-
can, and South American). Latinos are genetically admixed,
and previously published HCHS/SOL GWAS results indi-
cate that there are 3 major admixture groups representing
African, Amerindian, and European continental ancestries[6]. To apply HCHS/SOL ancestry findings and, to some
extent, replicate previous studies, we also generated three
groups: (1) Caribbean (Dominican, Puerto Rican), (2) Main-
land (Mexican, Central and South American), and (3) Cuban
[4,5]. However, it should be noted that previous Latino de-
mentia studies did not include South Americans and Cubans
[4,5].
Cardiovascular risk was calculated based on the partici-
pants’ visit 2 Framingham cardiovascular risk score
(FCRS) composed of age, total cholesterol (mg/dL), high-
density lipoprotein (HDL), cholesterol (mg/dL), systolic
blood pressure (based on the average of three readings in
mm Hg), blood pressure medication use, current smoking
status, and diabetes [22,23]. FCRSs in the range of 0–
100% were divided by 10, when modeled to allow direct
interpretation of relative risks in 10% FCRS CVD risk incre-
ments.
APOE genotyping was conducted on the SOL-INCA par-
ticipants who consented to genetic data collection
(Supplementary Fig. 1). The distribution of allele fre-
quencies varied by Latino background, as previously re-
ported [24]. We used a binary classification that groups
those with 1 or more APOE4 allele versus no APOE4 allele.
Additionally, a three-category indicator that separately clas-
sifies APOE2 allele carriers (1 or 0) was generated and
tested in sensitivity models. All analyses adjusting for
APOE4 were restricted to the subpopulation consenting for
genetic data collection. Descriptive characteristics
comparing differences between those that provided consent
and those that opted out are presented in Supplementary
Table 2.
Multivariable model covariables included sex, age (50–
59 years; 60–69 years; and 70 1 years), education (,12
years, 12 years, .12 years), and depressive symptoms at
HCHS/SOL visit 2 (Center for Epidemiologic Studies
Depression scale-10; CESD-10) [25]. In additional ana-
lyses, we considered age measured continuously (in years)
and dichotomously (,65 years and 65 1 years) to allow
comparison of findings of this report with those of previous
reports. We also considered education measured continu-
ously and generated estimates of MCI prevalence over
the number of years of education and at education levels
that better reflects the distribution of educational achieve-
ment in this cohort.
The analytic sample included 6377 enrolled participants
aged 50–86 years at HCHS/SOLV2. A flow chart detailing
the SOL-INCA sample and exclusion criteria is provided
in Supplementary Fig. 1. Given our interest in providing
MCI estimates for specific Latino groups, we excluded par-
ticipants (n5 120) who reported mixed Latino backgrounds
and participants (n 5 14) who did not provide background
information. We excluded participants (n 5 103) with
missing cognitive data needed to classify MCI. Additionally,
we excluded participants (n 5 85) who met criteria for sus-
pected severe cognitive impairment (,2 SD below the
normative mean on any cognitive domain and functional
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individuals (n 5 174) with missing values on any of the co-
variates of interest. The analytic sample size was 5881. The
excluded participants had similar age, sex, and Latino back-
ground distributions relative to those included in the analytic
sample.2.2. Statistical analyses
First, we provide descriptive statistics to characterize
the full sample (Table 1) and the MCI group (Table 2)
by a specific Latino background. Second, we profile differ-
ences in demographic, cardiovascular, behavioral, and ge-
netic risk for cognitively normal and MCI groups. Third,
we use survey logistic models to test the associations be-
tween MCI classification and Latino background group-
ings. We fit two models (Table 3) to sequentially derive
(1) crude and (2) sex-, age-, education-, FCRS-, and
CESD-10-adjusted odds ratios and their 95% confidence
intervals (CI). We fit an additional model to independently
adjust for 1 APOE4 (Table 4). For all the tested models,
we generated and plotted post hoc estimates of crude and
adjusted marginal probabilities and their 95% CIs to facil-
itate visualization of associations between the model cova-
riates and MCI classification. Fig. 1 details the crude
prevalence estimates. Supplementary Figs. 2 and 3 include
estimates for the additional operationalizations of age and
education described in the above sections. Fig. 2 provides
the adjusted estimates for all model covariates of interest.
Supplementary Fig. 4 provides these estimates using the
classified Latino groups. All analyses incorporated the
HCHS/SOL and SOL-INCA sampling design includingTable 1
Characteristics by Hispanic/Latino backgrounds in the Study of Latinos-Investiga
Dominican Central American Cuban
Age (years), % (SE)
50–59 43.97 (2.69) 40.83 (2.74) 33.33 (2.2
60–69 36.64 (2.81) 38.54 (2.72) 33.58 (2.2
701 19.39 (2.52) 20.63 (2.99) 33.10 (2.7
Education (years), % (SE)
,12 45.22 (2.83) 42.61 (2.64) 22.77 (2.0
12 20.13 (2.11) 19.47 (2.25) 25.48 (1.5
.12 34.65 (2.51) 37.92 (2.57) 51.75 (2.1
Sex, % (SE)
Female 60.32 (2.48) 60.99 (2.82) 48.59 (1.8
Framingham cardiovascular
risk score (FCRS), % (SE)
,10% 32.05 (2.34) 31.42 (2.47) 20.94 (1.3
10–,20% 31.33 (2.28) 27.48 (2.19) 29.74 (2.1
201% 36.62 (2.63) 41.10 (2.54) 49.32 (2.2
APOE4 status, % (SE)
Any 4 29.41 (2.44) 21.14 (3.04) 21.57 (1.7
Age (years), Mean (SD) 62.11 (7.68) 62.66 (8.99) 64.61 (6.8
FCRS (r 5 0%–100%), Mean (SD) 19.0 (15.0) 20.0 (17.0) 25.0 (14
CESD-10 (r 5 0–30), Mean (SD) 7.00 (6.14) 6.16 (7.07) 6.58 (5.3
Abbreviations: SD, standard deviation; SE, standard error; CESD, Center for Estratification, clustering, and probability weights using the
Stata statistical software (v.15.1, StataCorp, College Sta-
tion, TX) survey functionalities.3. Results
We present the SOL-INCA target population characteris-
tics in Table 1 and stratified characteristics for the MCI sub-
population in Table 2. The average age of the target
population was 63 6 8 years, about a quarter of the popula-
tion were aged 701 years, 55% were female, and 40% had
.12 years of education. High proportions of participants
met criteria for intermediate (32.3%) or high (39.1%)
CVD risk based on the FCRS. The prevalence of any
APOE4 was 22%, and the average CESD score was
6.6 6 6.2. Mexicans, Dominicans, and Central Americans
were slightly younger and more likely to have 12 years
of education. APOE4 prevalence was higher among Domin-
icans and Puerto Ricans, and FCRS were higher in Cubans
and Puerto Ricans.
Overall, 9.8% of diverse middle-aged and older Latinos
met NIA-AA research diagnostic criteria for MCI. The prev-
alence varied between Latino backgrounds with Puerto Ri-
cans having the highest MCI prevalence (12.9%) and
Cubans having the lowest (8.0%). MCI prevalence among
Central Americans, Dominicans, South Americans, and
Mexicans were 10.8%, 9.7%, 9.6%, and 9.5%, respectively
(Fig. 1).
MCI was higher among participants older than 70 years
(14.6% vs. 7.2% among 50–59 years; P , .0001) and those
with ,12 years of education (13.2% vs. 8.3% among more
than 12 years of education; P 5 .0001), high FCRStion of Neurocognitive Aging (SOL-INCA)
Mexican Puerto Rican South American Total P value
6) 44.38 (1.85) 33.99 (1.90) 39.10 (3.40) 39.24 (0.99) .000
8) 36.73 (1.53) 36.66 (2.03) 37.17 (2.93) 36.05 (0.97)
4) 18.89 (1.51) 29.36 (2.00) 23.73 (3.42) 24.71 (1.04)
2) 48.05 (1.89) 41.57 (2.04) 24.92 (3.00) 38.48 (1.08) .000
4) 20.14 (1.41) 22.59 (1.73) 18.55 (2.35) 21.78 (0.76)
0) 31.82 (1.82) 35.84 (2.14) 56.53 (3.44) 39.74 (1.02)
5) 56.33 (1.58) 52.98 (2.13) 56.38 (2.91) 54.53 (0.88) .000
9) 34.14 (1.48) 22.93 (1.46) 36.01 (3.11) 28.60 (0.78) .000
3) 35.30 (1.55) 31.67 (1.93) 35.18 (3.16) 32.28 (0.89)
0) 30.56 (1.50) 45.40 (1.94) 28.81 (3.21) 39.12 (0.97)
4) 19.60 (1.54) 25.18 (2.02) 16.64 (2.70) 22.12 (0.86) .006
8) 62.05 (8.22) 64.26 (8.46) 63.29 (9.55) 63.19 (8.18) .000
.0) 18.0 (15.0) 22.0 (15.0) 17.0 (15.0) 21.0 (16.0) .000
0) 5.65 (5.67) 8.28 (6.63) 6.04 (7.02) 6.51 (6.14) .000
pidemiologic Studies Depression Scale; APOE4, apolipoprotein E4.
Table 2
Mild cognitive impairment participants’ characteristics between Hispanic/Latino backgrounds
Dominican Central American Cuban Mexican Puerto Rican South American Total P value
Age (years), % (SE)
50–59 32.08 (7.81) 37.78 (7.31) 23.66 (6.05) 28.68 (4.27) 28.64 (5.50) 32.57 (8.88) 28.90 (2.59) .960
60–69 35.45 (6.97) 26.73 (6.37) 38.05 (6.31) 35.80 (4.86) 33.00 (5.37) 27.15 (8.67) 34.42 (2.74)
701 32.47 (8.38) 35.49 (9.52) 38.29 (7.79) 35.52 (5.86) 38.36 (6.57) 40.28 (10.94) 36.68 (3.26)
Education (years), % (SE)
,12 47.52 (7.93) 60.47 (7.73) 28.03 (5.61) 59.92 (5.15) 56.00 (6.09) 26.18 (10.55) 49.30 (2.82) .002
12 15.25 (6.34) 11.63 (4.93) 23.55 (5.79) 17.19 (3.68) 19.48 (4.97) 18.60 (8.45) 18.46 (2.19)
.12 37.23 (8.08) 27.91 (5.84) 48.42 (6.43) 22.89 (4.68) 24.52 (5.42) 55.21 (11.44) 32.24 (2.88)
Sex, % (SE)
Female 68.66 (8.55) 62.47 (7.47) 62.19 (6.44) 50.61 (5.47) 61.44 (6.35) 57.94 (9.90) 58.51 (3.03) .411
Framingham cardiovascular
risk score (FCRS), % (SE)
,10% 23.16 (6.62) 17.82 (4.58) 13.13 (3.63) 22.30 (3.79) 8.38 (2.05) 43.27 (10.57) 18.21 (1.79) .017
10–,20% 35.03 (7.03) 25.21 (5.88) 28.17 (6.85) 33.34 (4.71) 35.95 (6.19) 34.97 (9.22) 32.33 (2.69)
201% 41.81 (7.66) 56.97 (7.45) 58.70 (6.96) 44.35 (5.68) 55.67 (6.37) 21.76 (7.98) 49.46 (2.98)
APOE4 Status, % (SE)
Any 4 24.87 (8.58) 28.53 (10.85) 23.76 (6.91) 21.05 (5.82) 25.30 (6.32) 14.75 (7.06) 23.45 (2.96) .947
Age (years), Mean (SD) 65.19 (8.20) 65.19 (10.51) 66.23 (6.64) 66.07 (9.15) 66.63 (9.04) 65.56 (9.93) 66.04 (8.73) .97
FCRS (r 5 0%–100%), Mean (SD) 22.0 (14.0) 24.0 (16.0) 29.0 (15.0) 25.0 (20.0) 26.0 (16.0) 18.0 (18.0) 25.0 (18.0) .09
CESD-10 (r 5 0–30), Mean (SD) 9.32 (6.85) 7.68 (8.07) 9.38 (5.83) 7.52 (6.43) 12.00 (6.31) 10.60 (9.25) 9.21 (6.94) ,.0001
Abbreviations: SD, standard deviation; SE, standard error; CESD, Center for Epidemiologic Studies Depression; APOE4, Apolipoprotein E4.
Results are based on data from Hispanics/Latinos aged 50–86 years in the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA).
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P, .0001), and high depressive symptoms (14.2% vs. 6.3%
among low symptoms [21 SD below mean]; P , .0001)
(Fig. 1). MCI prevalence did not significantly vary by sex,
APOE4, or APOE2 genotypes.
In the MCI subpopulation, Latino groups had similar age,
sex, and APOE4 genotype distributions (Table 2). Education
level, CVD risk, and depression scores varied in Latino
groups. Those with Mexican (60%) and Central American
(60.5%) backgrounds were less likely to have completed a
high school education. Cubans (58.7%), Central Americans
(57%), and Puerto Ricans (55.7%) had higher cardiovascular
risk (FCRS 20%; risk for an event within 10 years), and
Puerto Ricans and South Americans had higher average
CESD scores.
Multivariable results and marginal estimates are pre-
sented in Table 3 and Fig. 2. In our fully adjusted model, Cu-
bans (7.3%) had consistently lower MCI prevalence relative
to Puerto Ricans (D 5 23.8%; P 5 .015), Mexicans
(D 5 23.4%; P 5 .025), South Americans (D 5 23.7%;
P 5 .069), and Central Americans (D 5 23.6%;
P 5 .048). Older age (70 years), higher FCRS, and higher
CESD scores were also significantly associated with higher
risk for MCI. Sex, educational attainment, and APOE geno-
type were not significantly associated with MCI. Group dif-
ferences remained quantitatively and qualitatively
unchanged after adjustments for APOE (Table 4).4. Discussion
Among diverse middle-aged and older Latinos, the
overall MCI prevalence was 9.8%. The prevalence variedbetween Latino backgrounds (Fig. 1) and was higher
among Puerto Ricans and lower in Cubans. MCI was
associated with higher CVD risk, which suggests that
CVD is an important contributor to cognitive decline
and impairment in Latinos. It also suggests that reducing
CVD risk potentially could reduce MCI and dementia
risk as well in this important and rapidly growing and
aging US population [11]. Elevated depressive symptoms
were also associated with higher risk of MCI, which has
been reported in the previous studies [26]. High Ab
levels have been also linked to incident depressive symp-
toms in cognitively normal older adults [27]. This raises
questions about MCI in relation to CVD, Ab, and effec-
tive changes co-occurring in the early stages of demen-
tia. The natural history of MCI and progression to
dementia in any population is unclear, but it is largely
unknown among diverse Latinos in the United States.
The SOL-INCA is a younger cohort, which affords op-
portunities to discover factors that can contribute to
and prevent dementia in this important but understudied
population.
MCI was higher among Caribbean than Mainland
Latinos in the SOL-INCA, particularly among Puerto Ri-
cans, but the differences were not as large as previously
reported [4,5]. One explanation for differences between
studies is that previous findings come from two indepen-
dent studies with differing cognitive protocols compared
with the single methodology used in the SOL-INCA.
Another explanation is that different diagnostic criteria
(e.g., cognitive impairment no dementia) were used in
the previous study, which could yield different MCI es-
timates. MCI rates in the SOL-INCA were similar to a
Table 3
Multivariable association between Hispanic/Latino backgrounds and MCI
status
M1 M2
OR [95% CI] OR [95% CI]
Background (ref: Cubans)
Dominican 1.22 [0.78; 1.92] 1.37 [0.86; 2.18]
Central American 1.38 [0.89; 2.15] 1.58* [1.00; 2.48]
Cuban 1.00 [1.00; 1.00] 1.00 [1.00; 1.00]
Mexican 1.20 [0.84; 1.72] 1.55* [1.06; 2.28]
Puerto Rican 1.69y [1.16; 2.45] 1.61* [1.10; 2.36]
South American 1.21 [0.72; 2.02] 1.60 [0.96; 2.64]
Sex (ref: Female)
Male 0.77 [0.56; 1.05]
Age (ref: 50–59)
60–69 1.17 [0.86; 1.58]
701 1.65* [1.09; 2.49]
Education, years (12 ref)
,12 1.28 [0.93; 1.75]
.12 0.98 [0.68; 1.42]
Framingham cardiovascular
risk score
1.21z [1.09; 1.34]
CESD-10 (r 5 0–30) 1.07z [1.05; 1.09]
NOTE.M1 is a crudemodel;M2 adjusts for sex, age, education; Framing-
ham cardiovascular risk score, and CESD-10.
Odds ratios for the Framingham Cardiovascular Risk Score are for a 10%
increase in the score.
Results are based on data fromHispanics/Latinos aged 50–86 years in the
Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA).
Abbreviation: CESD, Center for Epidemiologic Studies Depression
Scale.
*P , .05.
yP , .01.
zP , .001.
Table 4
Associations between FCRS, depressive symptoms, and APOE4 and MCI
status among Hispanics/Latinos aged 50–86 years in the SOL-INCA
M1 M2
OR [95% CI] OR [95% CI]
Background (ref: Cubans)
Dominican 1.24 [0.74; 2.09] 1.35 [0.79; 2.31]
Central American 1.73* [1.03; 2.89] 1.99* [1.17; 3.39]
Cuban 1.00 [1.00; 1.00] 1.00 [1.00; 1.00]
Mexican 1.20 [0.77; 1.87] 1.55 [0.97; 2.47]
Puerto Rican 1.68* [1.09; 2.60] 1.63* [1.05; 2.53]
South American 1.13 [0.63; 2.04] 1.51 [0.84; 2.70]
Age (ref: 50–59)
60–69 1.16 [0.83; 1.61]
701 1.57 [0.97; 2.56]
Education, years (12 ref)
,12 1.30 [0.89; 1.90]
.12 1.04 [0.67; 1.62]
Sex (ref: Female)
Male 0.76 [0.52; 1.11]
Framingham cardiovascular
risk score
1.22y [1.08; 1.38]
CESD-10 1.06z [1.04; 1.09]
APOE-status (No 4s ref)
Any 4 1.06 [0.74; 1.51]
NOTE.M1 is a crude model. M2 adjusts for Latino/Hispanic background,
age, sex, and education, Framingham cardiovascular risk, CESD-10, and
Apolipoprotein E4 (APOE4).
Odds ratios for the Framingham cardiovascular risk score are for a 10%
increase in the score.
Abbreviation: CESD, Center for Epidemiologic Studies Depression
Scale.
*P , .05.
yP , .01.
zP , .001.
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ban Texas, which also used the NIA-AA MCI diagnostic
criteria [5]. Additionally, the SOL-INCA MCI preva-
lence estimates were similar to African Americans and
whites of comparable age groups in the Atherosclerosis
Risk in Communities-Neurocognitive study (ARIC-
NCS) [28]. The SOL-INCA provides updated MCI prev-
alence estimates using present diagnostic criteria in a
single multisite study of diverse middle-aged and older
Latinos [18]. To our knowledge, this is the first compar-
ative large study of MCI in diverse and representative
Latinos.
The two major risk factors for MCI were cardiovascular
risk and elevated depressive symptoms. We found that for
each 10% increase in the FCRS, the odds of MCI increased
by 21%. This is important because nearly 40% of the total
SOL-INCA sample was in the FCRS high-risk group and
this proportion increased to 57% among Latinos who met
MCI criteria. Higher depressive symptoms were also associ-
ated with MCI prevalence. Depressive symptoms are
commonly seen in poststroke patients, and 63% of middle-
aged and older patients have evidence of asymptomatic brain
infarction [29]. Together, this evidence suggests that thedepressive symptoms found to be associated MCI could be
the behavioral manifestations of vascular brain injury and
not necessarily affective in nature. Our results highlight
the potential for mitigating cognitive disease burden
by reducing these modifiable factors in this higher risk
population.
Low education is a risk factor for MCI and ADRD re-
ported in previous studies comparing whites with popula-
tions facing socioeconomic and health disparities [4]. In
the SOL-INCA, the socioeconomic conditions between
diverse Latino groups were generally balanced, which,
we suggest, allowed us to strip away most of the “noise”
of socioeconomic imbalances to better see salient health-
related factors associated with cognitive decline and
MCI. Women had slightly higher MCI rates than men,
but were not significantly different. The SOL-INCA con-
sists of a younger cohort than most dementia studies of
adults older than 65 years of age in which women are
over-represented secondary to early male mortality. As
such, our middle-aged and older cohort would be less sus-
ceptible to bias due to selective mortality of men. Addition-
ally, the HCHS/SOL representative sampling of target
areas is less susceptible to recruitment sampling bias.
Fig. 1. Prevalence of mild cognitive impairment (MCI; unadjusted) between backgrounds, demographic, cardiovascular, and behavioral factors, and APOE4
status in the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). Abbreviations: CA, Central American; PR, Puerto Rican; SA, South Amer-
ican; SD, standard deviation; FCRS, Framingham cardiovascular risk score; CESD, Center for Epidemiologic Studies Depression Scale (CESD-10); APOE4,
apolipoprotein E4.
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education and female participants go on to convert MCI to
dementia at an increased rate.
We previously reported in SOL-INCA that APOE2
and APOE4 varied between Latino backgrounds with
Dominicans having the highest prevalence of APOE2
and APOE4 alleles [24]. In this study, we did not see
strong associations between MCI and APOE2 and
APOE4 genotypes among diverse Latino backgrounds.
APOE2 is relatively uncommon among Mainland
Amerindian-admixed populations, and our study may
have been underpowered to detect significant APOE2
protective effect differences between Latino back-
grounds. Our APOE4 findings replicate previous studies
that showed little to no association between APOE4 ge-
notype and MCI among diverse Latinos, regardless of
the background [5,8,9]. Our findings suggest that the eti-
ology of MCI may be different among African- and
Amerindian-admixed Latinos as compared with persons
of European ancestry. Although we anticipated some
relationship between APOE4 and MCI among Cubans
who have higher degrees of European ancestry [6],
such differences were not found in the SOL-INCA.
This may be related to European colonists originating
from southern Europe, which is a region with lowAPOE4 frequencies and different admixture patterns
compared with northern Europeans [30].
This study had several strengths and limitations. One of
the strengths was our inclusion of both cognitive impair-
ment and significant cognitive decline, which are both
NIA-AA MCI diagnostic criteria [18]. This was done to
limit identification of false-positive MCI cases in this
sample of diverse Latinos with low education levels. Pre-
vious research has demonstrated that estimating premor-
bid function reduces false-positive cases associated with
educational quality [21]. Although there may be some
lost sensitivity for detecting MCI cases, we anticipate
that our research diagnostic approach will improve identi-
fication of persons who will convert from MCI to demen-
tia. Additionally, omitting the cognitive decline diagnostic
criterion effectively doubled our MCI prevalence esti-
mates to levels seen in other research [4]. First, the PVT
overcomes major challenges in assessing Spanish
speakers’ premorbid cognition (i.e., reading level)
because Spanish-language pronunciations are regular.
Second, we leveraged the HCHS/SOL sampling proced-
ures that enabled the SOL-INCA to make population-
level inferences to targeted metropolitan areas. Our study
is somewhat limited by our brief cognitive assessment
battery, which relied on the participant’s self-reported
Fig. 2. Adjusted prevalence of mild cognitive impairment (MCI) and odds ratios (ORs) between Hispanic/Latino backgrounds, demographic, Framingham car-
diovascular risk score, depressive symptoms, and APOE4. Findings from the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA). Note 1:
Estimates are based on multivariable models that include Latino background, age, education, sex, Framingham cardiovascular risk score, and CESD-10.
Note 2: Odds ratios for the Framingham cardiovascular risk score are for a 10% increase in the score. Abbreviations: SD, standard deviation; FCRS, Framing-
ham cardiovascular risk score; CESD, Center for Epidemiologic Studies Depression Scale (CESD-10); APOE4, apolipoprotein E4.
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SOL-INCA, we used our mental status (SIS) to construct
our robust normative sample; however, SIS was not used
as a measure of cognitive decline. Although optional in
NIA-AA criteria, the SOL-INCA did not include infor-
mant reports. Including informants in the SOL-INCA to
corroborate participants’ self-reports could have improved
case identifications. Third, the SOL-INCA cohort is
younger than that of older studies of cognitive aging
and disorders among persons aged 65 years and older,
which could explain the low MCI rates reported by us.
It should be noted that our MCI findings among SOL-
INCA participants aged 70–80 years are comparable
with those of a recent study of Mexican Americans in
Texas and in ARIC-NCS [9]. Fourth, a sizable number
of Latinos did not consent to genetic testing, which
reduced the sample size of APOE analyses and statistical
power to detect APOE associations with MCI. Neverthe-
less, our sensitivity analyses suggested that our APOE re-
sults would not have changed. Fifth, this study lacked AD
biomarkers to examine the extent of preclinical AD.
Finally, we relied on the FCRS for estimating CVD risk;
however, the FCRS has not been validated in diverse
Latinos.5. Conclusions
MCI varied among Latino backgrounds, but less so
than in previous studies. APOE4 was not significantly
associated with increased risk for MCI, which suggests
that alternative etiologic factors may contribute to MCI
among diverse Hispanics/Latinos. We found that high
CVD risk and depressive symptoms were associated
with increased MCI prevalence. Both conditions are
modifiable, which suggests pathways for improving
healthy brain aging and reducing Latino and national
ADRD burden.Acknowledgments
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1. Systematic review: Latinos are a diverse group and
represent nearly 20% of the US. Currently, little to
nothing is known about mild cognitive impairment
(MCI) in diverse Latino backgrounds (e.g., Central
Americans). In this multisite, prospective cohort
study of diverse middle-aged and older Latinos
(N 5 6377), we found that 9.8% met MCI criteria,
and MCI prevalence significantly varied by age
among Latino groups.
2. Interpretation: Cardiovascular disease risk and
depressive symptoms were significant correlates of
MCI prevalence.
3. Future direction: Cardiovascular disease and depres-
sive symptoms are modifiable risk factors for MCI
among diverse Latinos that afford opportunities for
reducing dementia-disease burden in this large,
rapidly growing, but understudied population facing
health disparities.
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